Chargement en cours...
Inebilizumab: First Approval
Inebilizumab (Uplizna™; inebilizumab-cdon in the USA) is a humanised anti-CD19 monoclonal antibody being developed by Viela Bio for the treatment of a range of autoimmune diseases associated with CD19-expressing B cells. Inebilizumab targets and depletes CD19-expressing B cells through antibody-depe...
Enregistré dans:
| Publié dans: | Drugs |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer International Publishing
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7387876/ https://ncbi.nlm.nih.gov/pubmed/32729016 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01370-4 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|